[go: up one dir, main page]

EP1000023B1 - Nouveaux diazeniumdiolates derives d'amidine et d'enamine liberant du monoxyde d'azote, compositions les contenant, leurs utilisations et leurs procedes de fabrication - Google Patents

Nouveaux diazeniumdiolates derives d'amidine et d'enamine liberant du monoxyde d'azote, compositions les contenant, leurs utilisations et leurs procedes de fabrication Download PDF

Info

Publication number
EP1000023B1
EP1000023B1 EP98933062A EP98933062A EP1000023B1 EP 1000023 B1 EP1000023 B1 EP 1000023B1 EP 98933062 A EP98933062 A EP 98933062A EP 98933062 A EP98933062 A EP 98933062A EP 1000023 B1 EP1000023 B1 EP 1000023B1
Authority
EP
European Patent Office
Prior art keywords
substituted
unsubstituted
compound
benzyl
branched chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP98933062A
Other languages
German (de)
English (en)
Other versions
EP1000023A2 (fr
Inventor
Joseph A. Hrabie
Larry K. Keefer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of EP1000023A2 publication Critical patent/EP1000023A2/fr
Application granted granted Critical
Publication of EP1000023B1 publication Critical patent/EP1000023B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/023—Preparation; Separation; Stabilisation; Use of additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/04—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/06—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton
    • C07C251/08—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton being acyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C291/00—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00
    • C07C291/02—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C291/00—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00
    • C07C291/02—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds
    • C07C291/08—Azoxy compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Definitions

  • the present invention relates to nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, to compositions comprising such compounds, to methods of using such compounds and compositions, to a method for the preparation of nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates via the direct reaction of nitric oxide with amidines and enamines, and to a method of converting amines into such compounds.
  • Keefer et al. disclose, among others, the use of certain nucleophile/nitric oxide adducts as NO-releasing agents, i.e., in which the nucleophilic residue (Nuc) is a primary amine, a secondary amine or a polyamine.
  • nucleophilic residue Nuc
  • adducts offer many advantages over other currently available nitric oxide-releasing compounds, one disadvantage presented by the use of such adducts as pharmaceutical agents is the potential risk of release of nitrosamines, which are carcinogenic, upon decomposition and release of NO.
  • Another disadvantage of the adducts of primary amines is that they can be unstable even as solids due to a tendency to form traces of potentially explosive diazotates.
  • cupferron Another compound, which has the structure and which has been named cupferron, has been shown by Kubrina et al., Izvestia Akademii Nauk SSSR Seriia Biologicheskaia 6: 844-850 (1988 )) to generate NO in vivo.
  • cupferron have been shown to release NO in vivo by enzymatic oxidation ( Alston et al., J. Biol. Chem. 260: 4069-4074 (1985 )).
  • Keefer et al. in U.S. Patent No. 5,212,204 , have broadly described that an organic moiety may be linked via carbon to the N 2 O 2 - group.
  • This patent does not disclose an amidine or enamine structure as the nucleophile, nor does it teach the nature of the structural characteristics that an organic moiety must possess to cause the resulting N 2 O 2 - group to be a nitric oxide donor.
  • nitric oxide-releasing compounds in which the nitric oxide-releasing group N 2 O 2 - is bonded directly to a carbon atom and which can be prepared from compounds that do not include a nitrogen atom suitable for conversion to a diazeniumdiolate.
  • a related object of the present invention is to provide NO- and/or NO - -releasing derivatives of known pharmaceutical agents.
  • a more specific object is to provide NO- and/or NO - -releasing derivatives of known pharmaceutical agents whose nitrogen atoms do not provide suitable N-diazeniumdiolates as nitric oxide donors.
  • Yet another object of the present invention is to provide compositions comprising NO- and/or NO - -releasing derivatives of amidines and enamines.
  • a further object of the present invention is to provide methods of using NO- and/or NO - -releasing derivatives of amidine and enamine compounds, and compositions thereof.
  • the present invention provides NO- or NO - -releasing diazeniumdiolates which are derived from an enamine or an amidine and in which the N 2 O 2 - functional group is bonded to a carbon atom.
  • the present invention also provides compositions comprising such diazeniumdiolate compounds, and methods of using such compounds and compositions.
  • the present invention further provides a method of producing an NO- or NO - -releasing enamine- or amidine-derived diazeniumdiolate.
  • the present invention provides a method for the preparation of an NO- and/or NO - -releasing amidine derivative from an existing amino compound. The method comprises reaction of the amino compound with an acetamidating reagent followed by reaction with nitric oxide gas.
  • a novel class of nitric oxide-nucleophile adducts or diazeniumdiolates having as defined in the claims an amidine- or enamine-derived chemical linkage in which the N 2 O 2 - functionality is bound directly to a carbon atom of the linkage.
  • the present invention contemplates all NO-releasing diazeniumdiolates which include an amidine- or an enamine-derived chemical linkage in which the N 2 O 2 - functional group is bound to a carbon atom irrespective of the tautomer that is thermodynamically favored.
  • the electron movement or tautomerization for the enamines and for the amidines is the same conceptually, but in the case of the enamines it is the lone pair of electrons associated with the nitrogen atom which must be used in the reaction since there is no H on the enamine nitrogen.
  • the amidine- and enamine-based diazeniumdiolates of the present invention are advantageous in several respects. These compounds are not expected to decompose to carcinogenic nitrosamines.
  • the diazeniumdiolates of the present invention exhibit the full range of water solubility. Some of the diazeniumdiolates of the present invention are thus particularly useful where water insolubility is desirable, such as in stents, implants, prostheses and the like.
  • Many diazeniumdiolates of the present invention are characterized by long-term slow release of NO and can be used in coatings or the like. Further, these compounds do not bleed out of the coating, even after the NO has been released.
  • the diazeniumdiolates of the present invention are very stable solids and in solution are more heat stable than the previously described nitrogen analogs. Some can be recrystallized from boiling solvents without decomposition.
  • amidine-derived diazeniumdiolates may be further described in accordance with the following formulas: or wherein R 1 -R 5 can be a wide variety of substituents without departing from the scope of the present invention owing to the fact that any compound which includes the characteristics of the chemical linkage identified above is contemplated herein.
  • R 1 -R 3 are independently chosen from hydrogen, an unsubstituted or substituted C 1-12 straight chain alkyl, an unsubstituted or substituted C 3-12 branched chain alkyl, an unsubstituted or substituted C 3-12 straight chain olefinic, an unsubstituted or substituted C 3-12 branched chain olefinic, a substituted or unsubstituted C 3-8 cycloalkyl, a C 3-8 heterocyclic ring bound through a carbon atom and in which the heteroatom is oxygen or nitrogen, a substituted or unsubstituted naphthyl, a substituted or unsubstituted tetrahydronaphthyl, a substituted or unsubstituted octrahydronaphthyl, benzyl or substituted benzyl, substituted with up to three substituents, or a substituted or unsubstit
  • R 4 and R 5 are independently hydrogen, an unsubstituted or substituted C 1-12 straight chain alkyl, an unsubstituted or substituted C 3-12 branched chain alkyl, an unsubstituted or substituted C 3-12 straight chain olefinic, an unsubstituted or substituted C 3-12 branched chain olefinic, a substituted or unsubstituted benzyl, a substituted or unsubstituted phenyl, a substituted or unsubstituted piperazino, or a substituted or unsubstituted morpholino.
  • R 4 and R 5 also can be amino, an unsubstituted or substituted alkylamino, carboxyalkylamino, carboxydialkylamino, an unsubstituted or substituted tolyl, xylyl, anisyl, mesityl, nitro, an unsubstituted or substituted arylamino, an unsubstituted or substituted dialkylamino, an unsubstituted or substituted diarylamino, an unsubstituted or substituted acetyl, an unsubstituted or substituted acetoxy, carboxy, an unsubstituted or substituted carboxyalkyl, such as an unsubstituted or substituted carboxymethyl or an unsubstituted or substituted carboxyethyl, an unsubstituted or substituted alkylcarbonyl, thiol, an unsubstituted or substituted alkylthio, an unsubstituted or substituted al
  • R 1 -R 5 When any of the groups indicated above for R 1 -R 5 are identified as being substituted, such as when the C 1-12 straight chain alkyl, the C 3-12 branched chain alkyl, the C 3-12 straight chain olefinic, the C 3-12 branched chain olefinic, the C 3-8 cycloalkyl, the benzyl, piperazino, morpholino, alkylamino, arylamino, acetyl, acetoxy, carboxy, carboxymethyl, alkoxy or the like are substituted, they can be substituted with any moiety that does not destroy the NO-releasing character of the compounds and which, preferably, is biologically compatible.
  • substituents to the substituted R 1 -R 5 groups can include hydroxy, alkoxy, acyloxy, halo or benzyl, acetyl, carboxyl, carboxyalkyl, such as carboxymethyl, carboxyethyl, carboxyalkylamido, carboxydialkylamido, carboxamido, amino, alkylamino, dialkylamino, alkylcarbonyl, arylamino, diarylamino, cyano, tolyl, xylyl, mesityl, anisyl, pyrrolidinyl, formyl, dioxane, thiol, alkylthiol, aryl, heteroaryl, such as pyran, pyrrole, furan, thiophene, thiazole, pyrazole, pyridine, or pyrimidine, phenoxy, benzyloxy, phenylcarbonyl, benzylcarbonyl, nitrophenyl,
  • the substituents R 1 , R 2 , R 3 , R 4 and R 5 in various combinations, and together with the nitrogen atom or carbon atom to which they are bonded, can form unsubstituted or substituted cyclic or unsubstituted or substituted heterocyclic rings.
  • the rings that are formed are four member rings or layers.
  • R 1 and R 2 together with the nitrogen atoms to which they are bonded can form a C 2-8 heterocyclic ring.
  • R 1 and R 4 together with the nitrogen atom to which R 1 is bonded and with the carbon atom to which R 4 is bonded can form a C 3 -C 8 heterocyclic ring.
  • R 2 and R 3 can form a C 3-8 heterocyclic ring with the nitrogen atom to which they are bonded.
  • the heterocyclic ring can also include up to one additional heteroatom, such as oxygen, nitrogen or sulfur.
  • the heterocyclic rings formed by the different combinations of R 1 , R 2 , R 3 , R 4 and R 5 can be, for example, a piperazino, a morpholino, a hexamethyleneimino, an imidazolyl, a pyrrolidino, a piperidino or the like.
  • R 4 and R 5 together with the carbon atom to which they are bonded can form a C 3-8 cycloalkyl, or a heterocyclic such as tetrahydrofuranyl, dioxanyl or the like.
  • R 4 and R 5 together with the carbon atom to which they are bonded can form a 1,4-benzodioxane, 1,3-benzodioxole, tetrahydronaphthlene, octahydronaphthalene, piperazine, morpholine, tetrahydroquinoline, tetrahydroquinoxaline, or tetrahydroisoquinoline.
  • Each of the cyclic or heterocyclic rings formed with R 1 and R 2 , or R 2 and R 3 , or R 1 and R 4 , or R 4 and R 5 can be substituted with one or more substituents, including, by way of example, C 3-8 cycloalkyl, alkoxy, benzyl, fused benzene, phenyl, an alkoxy, acetyl, carboxyl, carboxymethyl, carboxyethyl, carboxamido, amino, alkyl amino, dialkylamino, pyrrolidine, dioxane, thiol or alkylthiol, or a heteroaryl such as pyran, pyrrole, furan, thiophene, thiazole, pyrazole, pyridine, or pyrimidine.
  • substituents including, by way of example, C 3-8 cycloalkyl, alkoxy, benzyl, fused benzene, phenyl, an alkoxy,
  • a compound of Formula III preferably is one in which R 1 and R 2 are hydrogen and R 3 is the entire substituent attached to an amine of a pharmaceutical agent such as, for example, tryptamine, serotonin, histamine, valcyclovir, adenosine, thyroxine, guanine, guanosine, ubenimex, glucosamine, mannosamine, mycosamine, sphingosine, thienamycin, penicillamine and rimantadine.
  • a pharmaceutical agent such as, for example, tryptamine, serotonin, histamine, valcyclovir, adenosine, thyroxine, guanine, guanosine, ubenimex, glucosamine, mannosamine, mycosamine, sphingosine, thienamycin, penicillamine and rimantadine.
  • the present invention provides a compound of Formula III, in which R 1 and R 2 are hydrogen and R 3 is the entire substituent attached to an amine of an amino acid.
  • the amino acid is preferably lysine, tryptophan or hydroxy-tryptophan.
  • R 1 -R 6 can be a wide variety of substituents without departing from the scope of the present invention owing to the fact that any compound which includes the characteristics of the chemical linkage identified above is contemplated herein.
  • R 1 , R 2 , R 5 and R 6 are independently hydrogen, an unsubstituted or substituted C 1-12 straight chain alkyl, an unsubstituted or substituted C 3-12 branched chain alkyl, an unsubstituted or substituted C 3-12 straight chain olefinic, an unsubstituted or substituted C 3-12 branched chain olefinic, a substituted or unsubstituted benzyl, a substituted or unsubstituted piperazino, a substituted or unsubstituted morpholino, amino, an unsubstituted or substituted alkylamino, an unsubstituted or substituted arylamino, an unsubstituted or substituted dialkylamino, an unsubstituted or substituted diarylamino, carboxyalkylamino, carboxydialkylamino, cyano, tolyl, xylyl
  • R 3 and R 4 are independently chosen from hydrogen, an unsubstituted or substituted C 1-12 straight chain alkyl, an unsubstituted or substituted C 3-12 branched chain alkyl, an unsubstituted or substituted C 3-12 straight chain olefinic, an unsubstituted or substituted C 3-12 branched chain olefinic, a substituted or unsubstituted C 3-8 cycloalkyl, a C 3-8 heterocyclic ring bound through a carbon atom and in which the heteroatom is oxygen or nitrogen, a substituted or unsubstituted naphthyl, a substituted or unsubstituted tetrahydronaphthyl, a substituted or unsubstituted octahydronaphthyl, benzyl or substituted benzyl, substituted with up to three substituents, or a substituted or unsubstituted phen
  • R 1 -R 5 When any of the groups indicated above for R 1 -R 5 are identified as being substituted, such as the C 1-12 straight chain alkyl, the C 3-12 branched chain alkyl, the C 3-12 straight chain olefinic, the C 3-12 branched chain olefinic, the C 3-8 cycloalkyl, the benzyl, piperazino, morpholino, alkylamino, arylamino acetyl, acetoxy carboxy, carboxymethyl alkoxy or the like, they can be substituted with any moiety that does not destroy the NO-releasing character of the compounds and which, preferably, is biologically compatible.
  • substituents to the substituted R 1 -R 5 groups can include hydroxy, alkoxy, acyloxy, halo or benzyl, acetyl, carboxyl, carboxyalkyl, such as carboxymethyl, carboxyethyl, carboxyalkylamido, carboxydialkylamido, carboxamido, amino, alkyl amino, dialkylamino, alkylcarbonyl, arylamino, diarylamino, tolyl, xylyl, mesityl, anisyl, pyrrolidine, formyl, dioxane, thiol, alkylthiol, aryl, heteroaryl, such as pyran, pyrrole, furan, thiophene, thiazole, pyrazole, pyridine, or pyrimidine, phenoxy, benzyloxy, phenylcarbonyl, benzylcarbonyl, nitrophenyl trialkylsilyl,
  • R 1 -R 6 of the compounds of Formula IV and Formula V in various combinations, and together with the nitrogen atom or carbon atom to which they are bonded and intervening atoms, can form heterocyclic rings.
  • a compound of Formula V in which R 3 and R 4 , together with the nitrogen atom to which they are bonded can form a C 3-8 heterocycle.
  • the heterocycle can be further substituted with a heteroatom.
  • R 2 and R 3 together with the nitrogen to which R 3 is bonded, can form a C 3-8 heterocycle.
  • the heterocycle can be further substituted with a heteroatom, or an aromatic ring, which can be substituted with a C 1-6 alkyl or a C 1-6 alkoxy.
  • R 5 and R 4 can form a C 3-8 heterocycle, which can also be substituted.
  • R 3 and R 4 together with the nitrogen atom to which they are bonded can form a C 3-8 heterocyclic ring or a C 3-8 substituted heterocyclic ring or a C 3-8 unsubstituted or substituted heterocyclic ring containing up to two additional heteroatoms selected from the group O, S, N.
  • R 5 and R 6 together with the carbon to which they are bonded can form a substituted or unsubstituted C 4-8 cycloalkyl.
  • R 1 -R 5 can be selected such that they represent the substituents attached to the amidine of nasal decongestants and ⁇ -adrenergic antagonists such as tetrahydrozoline, idazoxan, phentolamine, xylometazoline and the like.
  • the method comprises reacting an amidine, preferably an amidine of Formula Ia, IIa or IIIa, with gaseous NO in acetonitrile or a similar solvent to produce an N 2 O 2 - -containing compound.
  • an amidine preferably an amidine of Formula Ia, IIa or IIIa
  • gaseous NO in acetonitrile or a similar solvent
  • R 1 and R 4 together with the nitrogen atom to which R 1 is bonded and with the carbon atom to which R 4 is bonded can form a C 3 -C 8 heterocyclic ring.
  • the solvent is preferably chosen so that the starting amidine or enamine is soluble whereas the resulting N 2 O 2 - -containing product is insoluble and so precipitates as it forms in order to drive the reaction to completion.
  • Anhydrous and neutral solvents such as acetonitrile, tetrahydrofuran, dioxane and ether are preferred because they do not cause hydrolysis of the water-sensitive amidines and enamines.
  • it is anticipated that low yields of the desired products can also form in partly aqueous and/or basic solvents such as NaOMe in methanol or wet tetrahydrofuran among others, and such solvents may also be used.
  • the resulting compound in accordance with the method of the invention contains either one or two N 2 O 2 - functional groups depending upon the structure of the amidine reactant, as, for example, shown below.
  • an NO-releasing amidine-derived diazeniumdiolate can be illustrated by the reaction of 2-methyl-2-imidazoline with NO as follows:
  • the initial reaction products are the amidinium salts (either intramolecular or intermolecular)
  • standard metathesis reactions can be employed to change the cation to any pharmaceutically acceptable ion. This is illustrated above by the reaction involving sodium methoxide in methanol, which produces the disodium salt.
  • the intramolecular or intermolecular salt or a mixture thereof can be obtained; the reaction of 2-methyl-2-imidazoline with NO in NaOMe/MeOH to directly form the sodium salt is an example of such a reaction.
  • reaction of the above undeuterated compound with an NO dimer is as follows: The reaction is believed to stop at this stage due to steric hindrance and/or precipitation of the product from solution.
  • amidino tautomers cannot come into conjugation with this nitroso group, it does not serve as a source of NO, and since hydrolysis of the amidine competes with the first pathway, compounds derived from amidines of formula I release only small amounts of NO, but over a long period of time. In such cases, the reaction of an amidine with NO results in a sterically hindered compound of formula I, which is apparently inclined to break apart differently than previously reported, less hindered N 2 O 2 - compounds.
  • the enamine-derived diazeniumdiolates do not appear to release any NO - or N 2 O. Rather, they release small amounts of NO over prolonged periods of time (e.g., 1 week in phosphate-buffered saline). As with amidine-derived compounds, the mechanism of NO release is complicated by a competing hydrolysis mechanism as set forth below.
  • amidine-derived or enamine-derived diazeniumdiolates in accordance with the present invention can be formed as a salt, and preferably, a biologically acceptable salt.
  • the counterion is preferably any biologically acceptable acceptable counterion.
  • Such counterions can include, but are not limited to, sodium ion, potassium ion, quaternary ammonium ions, and the like.
  • Also provided by the present invention is a method of producing a nitric oxide-releasing compound from a compound containing a primary amine and/or a secondary amine.
  • Such reagents are generally acetimidates, for example, ethyl acetimidate, or thioimidates, for example, benzyl thioacetimidate.
  • the preferred reagent for use in the context of this method is that described in Shearer et al., Tetrahedron Letters 38(2): 179-182 (1997 ), so as to form an acetamidine derivative of the compound containing the primary amine and/or secondary amine, and (b) treating the acetamidine derivative with nitric oxide gas to form an amidine-derived diazeniumdiolate.
  • This method in accordance with the invention provides a method for preparing an amidine-based diazeniumdiolate in which the NO-releasing N 2 O 2 - functional group is bound to a carbon atom rather than to the original primary cr secondary amine.
  • the present invention also provides a composition, including a pharmaceutical composition, comprising a present inventive diazeniumdiolate.
  • the pharmaceutical composition additionally comprises a pharmaceutically acceptable carrier.
  • Suitable methods of administering a diazeniumdiolate composition of the present invention to an animal, such as a mammal are available, and, although more than one route can be used to administer a particular composition, a particular route can provide a more immediate and more effective reaction than another route.
  • Pharmaceutically acceptable carriers are also well-known to those who are skilled in the art. The choice of carrier will be determined, in part, both by the particular composition and by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of the pharmaceutical compositions of the present invention.
  • Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of the diazeniumdiolate dissolved in diluents, such as water or saline, (b) capsules, sachets or tablets, each containing a predetermined amount of the active ingredient, as solids or granules, (c) suspensions in an appropriate liquid, and (d) suitable emulsions. Solutions may also be formulated using known preservatives for amidine-based nasal decongestants.
  • Tablet forms can include one or more of lactose, mannitol, corn starch, potato starch, microcrystalline cellulose, acacia, gelatin, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, moistening agents, preservatives, flavoring agents, and pharmacologically compatible carriers.
  • Lozenge forms can comprise the active ingredient in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addition to the active ingredient, such carriers as are known in the art.
  • a flavor usually sucrose and acacia or tragacanth
  • pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addition to the active ingredient, such carriers as are known in the art.
  • the diazeniumdiolates of the present invention can be made into aerosol formulations to be administered via inhalation.
  • aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like.
  • Formulations suitable for parenteral administration include aqueous and non-aqueous solutions, isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.
  • the formulations can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, water, for injections, immediately prior to use.
  • Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.
  • the dose administered to an animal, particularly a human, in the context of the present invention should be sufficient to effect a therapeutic response in the animal over a reasonable time frame.
  • the dose will be determined by the strength of the particular compositions employed (taking into consideration, at least, the rate of NO evolution, the extent of NO evolution, and the bioactivity of any decomposition products derived from the diazeniumdiolates) and the condition of the animal, as well as the body weight of the animal to be treated.
  • the size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects that might accompany the administration of a particular composition.
  • a suitable dosage for internal administration is 0.01 to 100 mg/kg per day.
  • a preferred dosage is 0.01 to 35 mg/kg per day.
  • a more preferred dosage is 0.05 to 5 mg/kg per day.
  • a suitable concentration of a enamine- or amidine-derived diazeniumdiolate in pharmaceutical compositions for topical administration is 0.05 to 15% (by weight).
  • a preferred concentration is from 0.02 to 5%.
  • a more preferred concentration is from 0.1 to 3%.
  • the present invention provides methods of using a nitric oxide-releasing amidine- or enamine-derived diazeniumdiolate.
  • a method of treating an animal, such as a mammal, with a biological disorder treatable with nitric oxide is provided.
  • the method comprises administering to the animal, e.g., the mammal, in need thereof an amount of an enamine- or amidine-derived diazeniumdiolate sufficient to treat the biological disorder in the animal.
  • biological disorder can be any biological disorder, including hypertension, restenosis, impotency, and a biological disorder due to a genetic defect or infection with an infectious agent, such as a virus, bacterium or parasite, as long as the disorder is treatable with nitric oxide.
  • NO- and/or NO - -releasing compounds derived from amidines are advantageous inasmuch as amidines are present in many already approved medicinal agents, e.g., tranquilizers, ⁇ -adrenergic antagonists, like phentolamine, and nasal decongestants.
  • specific examples include tolazoline and diazoxide.
  • Other examples of amidine-containing compounds include methyl pyrimidine and 1,8-diamino octahydronaphthalene.
  • a method for treating an animal for infection with, for example, a virus, a bacterium, or a parasite.
  • the method comprises administering to the animal, e.g., the mammal, an amount of a diazeniumdiolate sufficient to treat the infection in the animal.
  • a method for treating an animal, such as a mammal, for cancer comprises administering to the animal, e.g., the mammal, an amount of diazeniumdiolate sufficient to prevent the growth or metastasis of the cancer in the animal or to render it more susceptible to radiation or chemotherapy.
  • a method for treating an inanimate object for the presence of a potentially infectious virus, bacterium, or parasite comprises contacting the inanimate object with an amount of a present inventive diazeniumdiolate sufficient to reduce the presence of the potentially infectious virus, bacterium or parasite.
  • a present inventive diazeniumdiolate sufficient to reduce the presence of the potentially infectious virus, bacterium or parasite.
  • potentially infectious is meant the capability of infecting an animal, such as a mammal.
  • the diazeniumdiolates derived from enamines and amidines in accordance with the present invention can be used to coat prostheses, stents, and medical implants, such as breast implants, prior to surgical introduction into the body as a means of reducing the risk of solid state carcinogenesis associated therewith, or as a means of preventing adhesion of platelets to the implants.
  • the prostheses and implants can be manufactured using an enamine- or amidine-derived diazeniumdiolate as an integral component of the starting materials. Medical devices incorporating an enamine- or amidine-derived diazeniumdiolate provide an invaluable two-pronged approach to the treatment of many biological disorders, providing useful medical structures that also advantageously provide local release of NO.
  • the diazeniumdiolates derived from enamines and amidines also have utility in the in vitro study of NO biology.
  • This example describes a generalized procedure for the preparation of NO- and/or NO - -releasing compounds from amidines.
  • This example describes the preparation of 2-methyl-2-imidazoline tetrakis(nitric oxide)adduct and its sodium salt.
  • This example describes the preparation of acetamidine tetrakis(nitric oxide)adduct.
  • This example describes the preparation of 2-iminopiperidine bis(nitric oxide)adduct.
  • This example describes the preparation of 2-cyclohexyl-2-imidazoline bis(nitric oxide)adduct.
  • This example describes the preparation of tetrahydrozoline bis(nitric oxide)adduct.
  • This example describes the preparation of idazoxan-bis(nitric oxide) adduct available from Research Biochemicals, Inc. (Natick, HA).
  • This example describes a general procedure for preparation of diazeniumdiolate derivatives of enamines.
  • Enamines were prepared from an equimolar mixture of an aldehyde and ketone and a wide variety of secondary amines via dehydration. Such methods are described in Hicknott, Tetrahedron 38: 1975-2050, and 3363-3446 (1982 ); Cook, Enamines: Synthesis, Structure and Reactions, Marcel Dekker, New York (1988 ); and Szmuszkovicz, "Enamines", Chapter 4, In advances in Org. Chem, Methods and Results, Wiley Interscience, New York (1963 ).
  • Preferred amines include dimethylamine, diethylamine, piperidine, pyrrolidine, morpholine and N-methyl-aniline.
  • This example describes the preparation of cyclohexanone morpholine enamine bis(nitric oxide) adduct.
  • This example describes the preparation of isobutyraldehyde morpholine enamine bis (nitric oxide) adduct.
  • This example describes the preparation of cyclohexanecarboxaldehyde morpholine enamine bis (nitric oxide) adduct.
  • This example describes the preparation of isobutyraldehyde piperidine enamine bis(nitric oxide) adduct (25).
  • This example describes the preparation of isobutyraldehyde pyrrolidine enamine bis (nitric oxide) adduct.
  • This example describes the preparation of isobutyraldehyde N-methylaniline enamine bis(nitric oxide) adduct.
  • This example describes the preparation of isobutyraldehyde N-methyl-p-toluidine enamine bis(nitric oxide) adduct.
  • This example describes the preparation of isobutyraldehyde N-methyl-p-anisidine enamine bis (nitric oxide) adduct.
  • This example describes the measurement of the production of NO and N 2 O by amidine/nitric oxide adducts.
  • This example describes the measurement of the time course of NO production by amidine and enamine nitric oxide adducts.
  • Example V tetrahydrozoline diazeniumdiolate
  • the compound of Example V showed an initial NO release rate of 3.64 x 10 -11 moles NO per minute per milligram of dissolved sample which decreased to 2.06 x 10 -11 moles NO per min. per mg. after 7 days and continued for several weeks although the last quantitative measurement showed an NO release rate of 9.00 x 10 -12 moles NO per min. per mg. 15 days after the beginning of the experiment.
  • Example VI Likewise, the compound of Example VI (idazoxan diazeniumdiolate) showed an initial NO release rate of 5.25 x 10 -11 moles NO/min./mg. which gradually increased to 1.41 x 10 -10 moles NO/min./mg. after 4 days and then gradually decreased, reaching zero (i.e., no more NO was being given off) by day 16.
  • the compound of Example VII (the diazeniumdiolate of the morpholine enamine of cyclohexanone) showed an initial NO release rate of 4.2 x 10 -11 mole NO/min./mg. which decreased with nearly first order kinetics to 1.8 x 10 -11 mole NO/min./mg. after 3 days and reached zero by day 7.
  • the enamine-derived diazeniumdiolate of Example VIII (from the morpholine enamine of isobutyraldehyde) showed an initial NO release rate of 3.7 x 10- 11 mole NO/min./mg. which rapidly decreased to a rate of 7.0 x 10 -12 mole NO/min./mg. and then remained at about this level for 4 days before slowly declining, reaching zero after 7 days.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Treating Waste Gases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (20)

  1. Composé d'amidine-diazéniumdiolate libérant de l'oxyde nitrique choisi parmi le groupe constitué de
    Figure imgb0043
    Figure imgb0044
     et
    Figure imgb0045
     dans lesquelles
    R1 à R3 sont indépendamment l'hydrogène, un groupe alkyle en C1 à C12 à chaîne droite non substitué ou substitué, un groupe alkyle en C3 à C12 à chaîne ramifiée non substitué ou substitué, un groupe alcényle en C3 à C12 à chaîne droite non substitué ou substitué, un groupe alcényle en C3 à C12 à chaîne ramifiée non substitué ou substitué, un groupe cycloalkyle en C3 à C8 substitué ou non substitué, un noyau hétérocyclique en C3 à C8 lié par un atome de carbone et dans lequel l'hétéroatome est un oxygène ou un azote, un groupe naphtyle substitué ou non substitué, un groupe tétrahydronaphtyle substitué ou non substitué, un groupe octahydronaphtyle substitué ou non substitué, un groupe benzyle ou benzyle substitué, substitué par jusqu'à trois substituants, ou un groupe phényle ou phényle substitué, substitué par jusqu'à trois substituants,
    R4 et R5 sont indépendamment choisis parmi l'hydrogène, un groupe alkyle en C1 à C12 à chaîne droite non substitué ou substitué, un groupe alkyle en C3 à C12 à chaîne ramifiée non substitué ou substitué, un groupe alcényle en C3 à C12 à chaîne droite non substitué ou substitué, un groupe alcényle en C3 à C12 à chaîne ramifiée non substitué ou substitué, un groupe benzyle substitué ou non substitué, un groupe phényle non substitué ou substitué, un groupe pipérazino substitué ou non substitué, un groupe morpholino substitué ou non substitué, un groupe amino, un groupe alkylamino non substitué ou substitué, un groupe arylamino non substitué ou substitué, un groupe dialkylamino non substitué ou substitué, un groupe diarylamino non substitué ou substitué, un groupe carboxyalkylamino, un groupe carboxydialkylamino, des groupes tolyle, xylyle, anisyle, mésityle non substitués ou substitués, un groupe acétyle non substitué ou substitué, un groupe acétoxy non substitué ou substitué, un groupe carboxy, un groupe carboxyméthyle non substitué ou substitué, un groupe carboxyéthyle non substitué ou substitué, un groupe alkylcarbonyle non substitué ou substitué, un groupe thiol, un groupe alkylthio non substitué ou substitué, un groupe alkoxy non substitué ou substitué, un groupe carboxamido, un groupe alkylcarboxamido non substitué ou substitué, ou un groupe dialkylcarboxamido non substitué ou substitué, un groupe phénoxy non substitué ou substitué, un groupe benzyloxy non substitué ou substitué, un groupe phénylcarbonyle, un groupe benzylcarbonyle, un groupe nitrophényle non substitué ou substitué, trialkylsilyle ou nitro,
    R1 et R2 conjointement avec les atomes d'azote auxquels ils sont liés forment un noyau hétérocyclique en C3 à C8 substitué ou non substitué, ou
    R2 et R3 conjointement avec les atomes d'azote auxquels ils sont liés forment un noyau hétérocyclique en C3 à C8 substitué ou non substitué, ou
    R1 et R4 conjointement avec l'atome d'azote auquel R1 est lié et avec l'atome de carbone auquel R4 est lié et avec l'atome de carbone intervenant forment un noyau hétérocyclique en C3 à C8 substitué ou non substitué, ou
    R4 et R5 conjointement avec l'atome de carbone auquel ils sont liés forment un groupe cycloalkyle en C3 à C8 non substitué ou substitué, ou un groupe hétérocyclique en C4 à C8 dans lequel l'hétéroatome est choisi parmi le groupe constitué de l'oxygène, de l'azote et du soufre, ou
    R4 et R5 conjointement avec l'atome de carbone auquel ils sont liés forment un groupe 1,4-benzodioxanne, 1,3-benzodioxole, tétrahydronaphtalène, octahydronaphtalène, pipérazine, morpholine, tétrahydroquinoléine, tétrahydroquinoxaline, tétrahydroisoquinoléine non substitué ou substitué.
  2. Composé selon la revendication 1 de formule
    Figure imgb0046
     dans laquelle
    R1 à R3 sont indépendamment l'hydrogène, un groupe alkyle en C1 à C12 à chaîne droite non substitué ou substitué, un groupe alkyle en C3 à C12 à chaîne ramifiée non substitué ou substitué, un groupe alcényle en C3 à C12 à chaîne droite non substitué ou substitué, un groupe alcényle en C3 à C12 à chaîne ramifiée non substitué ou substitué, un groupe cycloalkyle en C3 à C8 non substitué ou substitué, un noyau hétérocyclique en C3 à C8 lié par un atome de carbone et dans lequel l'hétéroatome est un atome d'oxygène ou d'azote, un groupe naphtyle substitué ou non substitué, un groupe tétrahydronaphtyle substitué ou non substitué, un groupe octahydronaphtyle substitué ou non substitué, un groupe benzyle ou benzyle substitué, substitué par jusqu'à trois substituants, ou un groupe phényle ou phényle substitué, substitué par jusqu'à trois substituants,
    R4 et R5 sont indépendamment choisis parmi l'hydrogène, un groupe alkyle en C1 à C12 à chaîne droite non substitué ou substitué, un groupe alkyle en C3 à C12 à chaîne ramifiée non substitué ou substitué, un groupe alcényle en C3 à C12 à chaîne droite non substitué ou substitué, un groupe alcényle en C3 à C12 à chaîne ramifiée non substitué ou substitué, un groupe benzyle substitué ou non substitué, un groupe phényle non substitué ou substitué, un groupe pipérazino substitué ou non substitué, un groupe morpholino substitué ou non substitué, un groupe amino, un groupe alkylamino non substitué ou substitué, un groupe arylamino non substitué ou substitué, un groupe dialkylamino non substitué ou substitué, un groupe diarylamino non substitué ou substitué, un groupe carboxyalkylamino, un groupe carboxydialkylamino, des groupes tolyle, xylyle, anisyle, mésityle non substitués ou substitués, un groupe acétyle non substitué ou substitué, un groupe acétoxy non substitué ou substitué, un groupe carboxy, un groupe carboxyméthyle non substitué ou substitué, un groupe carboxyéthyle non substitué ou substitué, un groupe alkylcarbonyle non substitué ou substitué, un groupe thiol, un groupe alkylthio non substitué ou substitué, un groupe alkoxy non substitué ou substitué, un groupe carboxamido, un groupe alkylcarboxamido non substitué ou substitué, ou un groupe dialkylcarboxamido non substitué ou substitué, un groupe phénoxy non substitué ou substitué, un groupe benzyloxy non substitué ou substitué, un groupe phénylcarbonyle, un groupe benzylcarbonyle, un groupe nitrophényle non substitué ou substitué, trialkylsilyle ou nitro,
    R1 et R2 conjointement avec les atomes d'azote auxquels ils sont liés forment un noyau hétérocyclique en C3 à C8 substitué ou non substitué, ou
    R2 et R3 conjointement avec les atomes d'azote auxquels ils sont liés forment un noyau hétérocyclique en C3 à C8 substitué ou non substitué, ou
    R1 et R4 conjointement avec l'atome d'azote auquel R1 est lié et avec l'atome de carbone auquel R4 est lié et avec l'atome de carbone intervenant forment un noyau hétérocyclique en C3 à C8 substitué ou non substitué, ou dans lequel R4 et R5 conjointement avec l'atome de carbone auquel ils sont liés forment un groupe cycloalkyle en C3 à C8 non substitué ou substitué, ou un groupe hétérocyclique en C4 à C8 dans lequel l'hétéroatome est choisi parmi le groupe constitué de l'oxygène, de l'azote et du soufre, ou
    R4 et R5 conjointement avec l'atome de carbone auquel ils sont liés forment en groupe 1,4-benzodioxanne, 1,3-benzodioxole, tétrahydronaphtalène, octahydronaphtalène, pipérazine, morpholine, tétrahydroquinoléine, tétrahydroquinoxaline, tétrahydroisoquinoléine non substitué ou substitué.
  3. Composé selon la revendication 1 de formule
    Figure imgb0047
     dans laquelle
    R1 a R3 sont indépendamment l'hydrogène, un groupe alkyle en C1 à C12 à chaîne droite non substitué ou substitué, un groupe alkyle en C3 à C12 à chaîne ramifiée non substitué ou substitué, un groupe alcényle en C3 à C12 à chaîne droite non substitué ou substitué, un groupe alcényle en C3 à C12 à chaîne ramifiée non substitué ou substitué, un groupe cycloalkyle en C3 à C8 substitué ou non substitué, un noyau hétérocyclique en C3 à C8 substitué ou non substitué lié par un atome de carbone et dans lequel l'hétéroatome est un atome d'oxygène ou d'azote, un groupe naphtyle substitué ou non substitué, un groupe tétrahydronaphtyle substitué ou non substitué, un groupe octahydronaphtyle substitué ou non substitué, un groupe benzyle ou benzyle substitué, substitué par jusqu'à trois substituants, ou un groupe phényle ou phényle substitué, substitué par jusqu'à trois substituants,
    R4 est l'hydrogène, un groupe alkyle en C1 à C12 à chaîne droite non substitué ou substitué, un groupe alkyle en C3 à C12 à chaîne ramifiée non substitué ou substitué, un groupe alcényle en C3 à C12 à chaîne droite non substitué ou substitué, un groupe alcényle en C3 à C12 à chaîne ramifiée non substitué ou substitué, un groupe benzyle substitué ou non substitué, un groupe phényle non substitué ou substitué, un groupe pipérazino substitué ou non substitué, un groupe morpholino substitué ou non substitué, un groupe amino, un groupe alkylamino non substitué ou substitué, un groupe arylamino non substitué ou substitué, un groupe dialkylamino non substitué ou substitué, un groupe diarylamino non substitué ou substitué, un groupe carboxyalkylamino, un groupe carboxydialkylamino, des groupes tolyle, xylyle, anisyle, mésityle non substitués ou substitués, un groupe acétyle non substitué ou substitué, un groupe acétoxy non substitué ou substitué, un groupe carboxy, un groupe carboxyméthyle non substitué ou substitué, un groupe carboxyéthyle non substitué ou substitué, un groupe alkylcarbonyle non substitué ou substitué, un groupe thiol, un groupe alkylthio non substitué ou substitué, un groupe alkoxy non substitué ou substitué, un groupe carboxamido, un groupe alkylcarboxamido non substitué ou substitué, ou un groupe dialkylcarboxamido non substitué ou substitué, un groupe phénoxy non substitué ou substitué, un groupe benzyloxy non substitué ou substitué, un groupe phénylcarbonyle, un groupe benzylcarbonyle, un groupe nitrophényle non substitué ou substitué, trialkylsilyle ou nitro,
    R1 et R2 conjointement avec les atomes d'azote auxquels ils sont liés forment un noyau hétérocyclique en C3 à C8 substitué ou non substitué, ou
    R2 et R3 conjointement avec les atomes d'azote auxquels ils sont liés forment un noyau hétérocyclique en C3 à C8 substitué ou non substitué, ou
    R1 et R4 conjointement avec l'atome d'azote auquel R1 est lié et avec l'atome de carbone auquel R4 est lié et avec l'atome de carbone intervenant forment un noyau hétérocyclique en C3 à C8 substitué ou non substitué.
  4. Composé selon la revendication 1 de formule
    Figure imgb0048
     dans laquelle
    R1 à R3 sont indépendamment l'hydrogène, un groupe alkyle en C1 à C12 à chaîne droite non substitué ou substitué, un groupe alkyle en C3 à C12 à chaîne ramifiée non substitué ou substitué, un groupe alcényle en C3 à C12 à chaîne droite non substitué ou substitué, un groupe alcényle en C3 à C12 à chaîne ramifiée non substitué ou substitué, un groupe cycloalkyle en C3 à C8 substitué ou non substitué, un noyau hétérocyclique en C3 à C8 lié par un atome de carbone et dans lequel l'hétéroatome est un atome d'oxygène ou d'azote, un groupe naphtyle substitué ou non substitué, un groupe tétrahydronaphtyle substitué ou non substitué, un groupe octahydronaphtyle substitué ou non substitué, un groupe benzyle ou benzyle substitué, substitué par jusqu'à trois substituants, ou un groupe phényle ou phényle substitué, substitué par jusqu'à trois substituants,
    R1 et R2 conjointement avec les atomes d'azote auxquels ils sont liés forment un noyau hétérocyclique en C3 à C8 substitué ou non substitué, ou
    R2 et R3 conjointement avec les atomes d'azote auxquels ils sont liés forment un noyau hétérocyclique en C3 à C8 substitué ou non substitué.
  5. Composé selon l'une quelconque des revendications 1 à 4, dans lequel le substituant sur un groupe substitué est un groupe alkoxy, acyloxy, hydroxy, halogéno, benzyle, acétyle, carboxyle, carboxyalkyle, carboxyalkylamido, carboxydialkylamido, alkylcarbonyle, arylamino, diarylamino, cyano, tolyle, xylyle, mésityle, anisyle, carboxamido, amino, alkylamino, dialkylamino, formyle, dioxanne, thiol, alkylthiol, aryle, hétéroaryle, ou phénoxy, benzyloxy, phénylcarbonyle, benzylcarbonyle, nitrophényle, trialkylsilyle, nitro, sulfonyle, nitrobenzyle, trialkylammonium, alkyle, cycloalkyle, tétrahydrofurannyle, tétrahydropyrannyle, pipéridinyle ou morpholinyle.
  6. Composé selon l'une quelconque des revendications 1 à 4, dans lequel le substituant est un groupe hétéroaryle choisi parmi le groupe constitué du groupe pyrrolyle, furannyle, thiophényle, thiazolyle, pyrazolyle, pyrannyle, pyridinyle ou pyrimidinyle.
  7. Composé selon l'une quelconque des revendications 1 à 4, dans lequel le substituant sur le groupe substitué est un groupe benzyle, tolyle, carboxyle, carboxyalkyle, dialkylamino, arylamino ou diarylamino.
  8. Composé selon la revendication 4, dans lequel R1 et R2 sont l'hydrogène et R3 est le substituant entier lié à une aminé d'un composé choisi parmi le groupe constitué d'un aminoacide, de tryptamine, de sérotonine, d'histamine, de valacyclovir, d'adénosine, de thyroxine, de guanine, de guanosine, d'ubenimex, de glucosamine, de mannosamine, de mycosamine, de sphingosine, de thiénamycine, de pénicillamine et de rimantadine.
  9. Composé selon la revendication 8, dans lequel ledit aminoacide est choisi parmi le groupe constitué de lysine, de tryptophane et d'hydroxytryptophane.
  10. Composé d'énamine-diazéniumdiolate libérant de l'oxyde nitrique choisi parmi le groupe constitué de
    Figure imgb0049
     et
    Figure imgb0050
     dans lesquelles
    R1, R2, R5 et R6 sont indépendamment l'hydrogène, un groupe alkyle en C1 à C12 à chaîne droite non substitué ou substitué, un groupe alkyle en C3 à C12 à chaîne ramifiée non substitué ou substitué, un groupe alcényle en C3 à C12 à chaîne droite non substitué ou substitué, un groupe alcényle en C3 à C12 à chaîne ramifiée non substitué ou substitué, un groupe benzyle substitué ou non substitué, un groupe phényle substitué ou non substitué, un groupe pipérazino substitué ou non substitué, un groupe morpholino substitué ou non substitué, un groupe amino, un groupe alkylamino non substitué ou substitué, un groupe arylamino non substitué ou substitué, un groupe dialkylamino non substitué ou substitué, un groupe diarylamino non substitué ou substitué, un groupe carboxyalkylamino, un groupe carboxydialkylamino, un groupe cyano, des groupes tolyle, xylyle, anisyle, mésityle substitués ou non substitués, un groupe acétyle non substitué ou substitué, un groupe acétoxy non substitué ou substitué, un groupe carboxy, un groupe carboxyméthyle non substitué ou substitué, un groupe carboxyéthyle non substitué ou substitué, un groupe alkylcarbonyle non substitué ou substitué, un groupe thiol, un groupe alkylthio non substitué ou substitué, un groupe alkoxy non substitué ou substitué, un groupe carboxamido, un groupe alkylcarboxamido non substitué ou substitué, ou un groupe dialkylcarboxamido non substitué ou substitué, un groupe phénoxy substitué ou non substitué, un groupe benzyloxy substitué ou non substitué, un groupe phénylcarbonyle, un groupe benzylcarbonyle, un groupe nitrophényle substitué ou non substitué, trialkylsilyle ou nitro,
    R1 et R2 conjointement avec l'atome de carbone auquel ils sont liés peuvent former un groupe cycloalkyle en C4 à C8 substitué ou non substitué, ou
    R2 et R3 conjointement avec l'atome d'azote auquel ils sont liés forment un groupe cycloalkyle en C3 à C8 substitué ou non substitué, ou
    R3 et R4 sont un groupe alkyle en C1 à C12 à chaîne droite non substitué ou substitué, un groupe alkyle en C3 à C12 a chaîne ramifiée non substitué ou substitué, un groupe alcényle en C3 à C12 à chaîne droite non substitué ou substitué, un groupe alcényle en C3 à C12 à chaîne ramifiée non substitué ou substitué, un groupe cycloalkyle en C3 à C8 substitué ou non substitué, un noyau hétérocyclique en C3 à C8 substitué ou non substitué lié par un atome de carbone et dans lequel l'hétéroatome est un atome d'oxygène ou d'azote, un groupe naphtyle substitué ou non substitué, un groupe tétrahydronaphtyle substitué ou non substitué, un groupe octahydronaphtyle substitué ou non substitué, un groupe benzyle ou benzyle substitué, substitué par jusqu'à trois substituants, ou un groupe phényle ou phényle substitué, substitué par jusqu'à trois substituants, ou
    R3 et R4 conjointement avec l'atome d'azote auxquels ils sont liés peuvent former un noyau hétérocyclique en C3 à C8 ou un noyau hétérocyclique en C3 à C8 substitué ou un noyau hétérocyclique en C3 à C8 non substitué ou substitué contenant jusqu'à deux hétéroatomes supplémentaires choisis parmi le groupe O, S et N, ou
    R1 et R6 conjointement avec C=C-C par lequel ils sont liés forment un groupe cycloalkyle non substitué ou substitué, ou
    R5 et R6 conjointement avec l'atome de carbone auquel ils sont liés peuvent former un cycloalkyle en C4 à C8 substitué ou non substitué.
  11. Composé selon la revendication 10 de formule
    Figure imgb0051
     dans laquelle R1 et R2 sont indépendamment l'hydrogène, un groupe alkyle en C1 à C12 à chaîne droite non substitué ou substitué, un groupe alkyle en C3 à C12 à chaîne ramifiée non substitué ou substitué, un groupe alcényle en C3 à C12 à chaîne droite non substitué ou substitué, un groupe alcényle en C3 à C12 à chaîne ramifiée non substitué ou substitué, un groupe benzyle substitué ou non substitué, un groupe phényle substitué ou non substitué, un groupe pipérazino substitué ou non substitué, un groupe morpholino substitué ou non substitué, un groupe amino, un groupe alkylamino non substitué ou substitué, un groupe arylamino non substitué ou substitué, un groupe dialkylamino non substitué ou substitué, un groupe diarylamino non substitué ou substitué, un groupe carboxyalkylamino, un groupe carboxydialkylamino, un groupe cyano, des groupes tolyle, xylyle, anisyle, mésityle substitués ou non substitués, un groupe acétyle non substitué ou substitué, un groupe acétoxy non substitué ou substitué, un groupe carboxy, un groupe carboxyméthyle non substitué ou substitué, un groupe carboxyéthyle non substitué ou substitué, un groupe alkylcarbonyle non substitué ou substitué, un groupe thiol, un groupe alkylthio non substitué ou substitué, un groupe alkoxy non substitué ou substitué, un groupe carboxamido, un groupe alkylcarboxamido non substitué ou substitué, ou un groupe dialkylcarboxamido non substitué ou substitué, un groupe phénoxy substitué ou non substitué, un groupe benzyloxy substitué ou non substitué, un groupe phénylcarbonyle, un groupe benzylcarbonyle, un groupe nitrophényle substitué ou non substitué, trialkylsilyle ou nitro,
    R3 et R4 sont un groupe alkyle en C1 à C12 à chaîne droite non substitué ou substitué, un groupe alkyle en C3 à C12 à chaîne ramifiée non substitué ou substitué, un groupe alcényle en C3 à C12 à chaîne droite non substitué ou substitué, un groupe alcényle en C3 à C12 à chaîne ramifiée non substitué ou substitué, un groupe cycloalkyle en C3 à C8 substitué ou non substitué, un noyau hétérocyclique en C3 à C8 substitué ou non substitué lié par un atome de carbone et dans lequel l'hétéroatome est un atome d'oxygène ou d'azote, un groupe naphtyle substitué ou non substitué, un groupe tétrahydronaphtyle substitué ou non substitué, un groupe octahydronaphtyle substitué ou non substitué, un groupe benzyle ou benzyle substitué, substitué par jusqu'à trois substituants, ou un groupe phényle ou phényle substitué, substitué par jusqu'à trois substituants.
  12. Composé selon la revendication 10 de formule
    Figure imgb0052
     dans laquelle R5 et R6 sont indépendamment l'hydrogène, un groupe alkyle en C1 à C12 à chaîne droite non substitué ou substitué, un groupe alkyle en C3 à C12 a chaîne ramifiée non substitué ou substitué, un groupe alcényle en C3 à C12 à chaîne droite non substitué ou substitué, un groupe alcényle en C3 à C12 à chaîne ramifiée non substitué ou substitué, un groupe benzyle substitué ou non substitué, un groupe phényle substitué ou non substitué, un groupe pipérazino substitué ou non substitué, un groupe morpholino substitué ou non substitué, un groupe amino, un groupe alkylamino non substitué ou substitué, un groupe arylamino non substitué ou substitué, un groupe dialkylamino non substitué ou substitué, un groupe diarylamino non substitué ou substitué, un groupe carboxyalkylamino, un groupe carboxydialkylamino, un groupe cyano, des groupes tolyle, xylyle, anisyle, mésityle substitués ou non substitués, un groupe acétyle non substitué ou substitué, un groupe acétoxy non substitué ou substitué, un groupe carboxy, un groupe carboxyméthyle non substitué ou substitué, un groupe carboxyéthyle non substitué ou substitué, un groupe alkylcarbonyle non substitué ou substitué, un groupe thiol, un groupe alkylthio non substitué ou substitué, un groupe alkoxy non substitué ou substitué, un groupe carboxamido, un groupe alkylcarboxamido non substitué ou substitué, ou un groupe dialkylcarboxamido non substitué ou substitué, un groupe phénoxy substitué ou non substitué, un groupe benzyloxy substitué ou non substitué, un groupe phénylcarbonyle, un groupe benzylcarbonyle, un groupe nitrophényle substitué ou non substitué, trialkylsilyle ou nitro,
    R3 et R4 sont un groupe alkyle en C1 à C12 à chaîne droite non substitué ou substitué, un groupe alkyle en C3 à C12 à chaîne ramifiée non substitué ou substitué, un groupe alcényle en C3 à C12 à chaîne droite non substitué ou substitué, un groupe alcényle en C3 à C12 à chaîne ramifiée non substitué ou substitué, un groupe cycloalkyle en C3 à C8 substitué ou non substitué, un noyau hétérocyclique en C3 à C8 substitué ou non substitué lié par un atome de carbone et dans lequel l'hétéroatome est un atome d'oxygène ou d'azote, un groupe naphtyle substitué ou non substitué, un groupe tétrahydronaphtyle substitué ou non substitué, un groupe octahydronaphtyle substitué ou non substitué, un groupe benzyle ou benzyle substitué, substitué par jusqu'à trois substituants, ou un groupe phényle ou phényle substitué, substitué par jusqu'à trois substituants.
  13. Composé selon la revendication 12, dans lequel, dans la formule V, R2 et R3, conjointement avec l'atome de carbone et d'azote auquel ils sont liés, forment un groupe cycloalkyle en C3 à C8.
  14. Composé selon la revendication 13, dans lequel le groupe cycloalkyle en C3 à C8 est substitué par un hétéroatome.
  15. Composé selon la revendication 12, dans lequel R5 et R6, conjointement avec C=C-C par lequel ils sont liés, forment un hydrocarbure alicyclique en C3 à C12.
  16. Composé selon la revendication 11, dans lequel R3 et R4, conjointement avec l'atome d'azote auquel ils sont liés, forment un groupe cycloalkyle en C3 à C12.
  17. Composé selon la revendication 16, dans lequel le groupe cycloalkyle en C3 à C8 est en outre substitué par un hétéroatome, ou un noyau aromatique, qui peut être substitué par un groupe alkyle en C1 à C6 ou un groupe alkoxy en C1 à C6, et R1 et R2 peuvent former un groupe cycloalkyle en C3 à C8.
  18. Utilisation d'un composé selon l'une quelconque des revendications 1 à 17 pour préparer un médicament destiné à traiter un animal présentant un trouble biologique pouvant être traité par l'oxyde nitrique.
  19. Procédé pour produire le composé d'amidine-diazéniumdiolate libérant de l'oxyde nitrique selon l'une quelconque des revendications 1 à 9 a partir d'un composé contenant une aminé, dans lequel ladite aminé est une aminé primaire ou une aminé secondaire, ledit procédé comprenant:
    (a) le traitement de l'aminé par un agent d'acétamidation afin de former un dérivé de l'acétamidine du composé contenant l'aminé, et
    (b) le traitement du dérivé de l'acétamidine avec un gaz oxyde nitrique afin de former un diazéniumdiolate dérivé de l'amidine.
  20. Composé selon l'une quelconque des revendications 1 à 17 pour utilisation dans le traitement d'un animal présentant un trouble biologique pouvant être traité par l'oxyde nitrique.
EP98933062A 1997-07-03 1998-07-01 Nouveaux diazeniumdiolates derives d'amidine et d'enamine liberant du monoxyde d'azote, compositions les contenant, leurs utilisations et leurs procedes de fabrication Expired - Lifetime EP1000023B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5169097P 1997-07-03 1997-07-03
US51690P 1997-07-03
PCT/US1998/013723 WO1999001427A2 (fr) 1997-07-03 1998-07-01 Nouveaux diazeniumdiolates derives d'amidine et d'enamine liberant du monoxyde d'azote, compositions les contenant, leurs utilisations et leurs procedes de fabrication

Publications (2)

Publication Number Publication Date
EP1000023A2 EP1000023A2 (fr) 2000-05-17
EP1000023B1 true EP1000023B1 (fr) 2011-02-23

Family

ID=21972800

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98933062A Expired - Lifetime EP1000023B1 (fr) 1997-07-03 1998-07-01 Nouveaux diazeniumdiolates derives d'amidine et d'enamine liberant du monoxyde d'azote, compositions les contenant, leurs utilisations et leurs procedes de fabrication

Country Status (8)

Country Link
US (4) US6232336B1 (fr)
EP (1) EP1000023B1 (fr)
JP (2) JP4856295B2 (fr)
AT (1) ATE499343T1 (fr)
AU (1) AU726861B2 (fr)
CA (1) CA2293501A1 (fr)
DE (1) DE69842142D1 (fr)
WO (1) WO1999001427A2 (fr)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1000023B1 (fr) * 1997-07-03 2011-02-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES Nouveaux diazeniumdiolates derives d'amidine et d'enamine liberant du monoxyde d'azote, compositions les contenant, leurs utilisations et leurs procedes de fabrication
US6207713B1 (en) * 1997-09-17 2001-03-27 Eric T. Fossel Topical and oral delivery of arginine to cause beneficial effects
US7629384B2 (en) * 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
US7914814B2 (en) * 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
CA2254645A1 (fr) * 1998-11-23 2000-05-23 Pulmonox Medical Corporation Methode et appareil pour traiter les infections respiratoires par l'inhalation d'oxyde nitrique
US20070086954A1 (en) * 1998-11-23 2007-04-19 Miller Christopher C Method and apparatus for treatment of respiratory infections by nitric oxide inhalation
FR2794647A1 (fr) * 1999-06-11 2000-12-15 Centre Nat Rech Scient Compositions pharmaceutique comprenant du no ou au moins un compose capable de liberer ou d'induire la formation de no dans les cellules
US7516742B2 (en) * 1999-11-24 2009-04-14 Cardinal Health 207, Inc. Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients with intermittent dosing
US6410622B1 (en) * 2000-09-11 2002-06-25 Gregory W. Endres Method of preventing fouling organisms in marine environments and polymer-bound nitric oxide/nitric oxide-releasing compositions usable therefor
US6797743B2 (en) * 2000-09-27 2004-09-28 Michigan Biotechnology Institute Antimicrobial polymer
US7122018B2 (en) * 2000-12-26 2006-10-17 Sensormedics Corporation Device and method for treatment of wounds with nitric oxide
US6432077B1 (en) * 2000-12-26 2002-08-13 Sensormedics Corporation Device and method for treatment of surface infections with nitric oxide
AU2002338528B2 (en) 2001-05-02 2008-01-24 Nicox S.A. Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
US6673338B1 (en) 2001-09-10 2004-01-06 The United States Of America As Represented By The Department Of Health And Human Services Nitric oxide-releasing imidate and thioimidate diazeniumdiolates, compositions, uses thereof and method of making same
DE10162114A1 (de) * 2001-12-12 2003-06-26 Schering Ag Neue Amidin-Derivate und deren Verwendung in Arzneimitteln
US6939554B2 (en) * 2002-02-05 2005-09-06 Michigan Biotechnology Institute Antimicrobial polymer
US7919075B1 (en) * 2002-03-20 2011-04-05 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices
WO2003080730A1 (fr) 2002-03-20 2003-10-02 Michigan Biotechnology Institute Materiau polymerique conducteur
CA2480033C (fr) * 2002-03-21 2011-05-10 The University Of Utah Research Foundation Utilisation in vivo de donneurs d'oxyde nitrique actives par la glutathion s-transferase
US7273616B2 (en) * 2002-05-10 2007-09-25 The Trustees Of Columbia University In The City Of New York Genetically engineered cell lines and systems for propagating Varicella zoster virus and methods of use thereof
US6949530B2 (en) * 2002-07-18 2005-09-27 The United States Of America As Represented By The Department Of Health And Human Services Nitric oxide-releasing amidine diazeniumdiolates, compositions and uses thereof and method of making same
JP2005534485A (ja) 2002-08-02 2005-11-17 アメリカ合衆国 架橋した一酸化窒素−放出ポリアミン被覆基質、それを含む組成物及びその製造方法
US20050080021A1 (en) * 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders
US20050080024A1 (en) * 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives for the treatment of cardiovascular disorders
US20040033480A1 (en) * 2002-08-15 2004-02-19 Wong Norman C.W. Use of resveratrol to regulate expression of apolipoprotein A1
US6951902B2 (en) * 2002-08-16 2005-10-04 Michigan Biotechnology Institute Two dimensional polymer that generates nitric oxide
US7531133B2 (en) * 2002-09-10 2009-05-12 Pulmonox Technologies Corporation Use of nitric oxide gas in an extracorporeal circuitry to treat blood plasma
WO2005011575A2 (fr) * 2003-07-25 2005-02-10 The University Of Akron Stabilisation et declenchement ionique de la liberation d'oxyde nitrique
WO2005018561A2 (fr) * 2003-08-20 2005-03-03 Nitromed, Inc. Composes cardiovasculaires nitroses et nitrosyles, compositions et procedes d'utilisation
EP1668008A4 (fr) * 2003-08-28 2009-02-25 Nitromed Inc Composes diuretiques nitroses et nitrosyles, compositions et procedes d'utilisation correspondants
US8703066B2 (en) * 2004-01-07 2014-04-22 Noxilizer, Inc. Sterilization system and method
US8017074B2 (en) 2004-01-07 2011-09-13 Noxilizer, Inc. Sterilization system and device
EP1718286A4 (fr) * 2004-01-22 2010-03-31 Nicox Sa Composes nitroses et/ou nitrosyles, compositions et procede pour les utiliser
JP2007522135A (ja) * 2004-01-30 2007-08-09 ザ ジョンズ ホプキンス ユニバーシティ ニトロキシル前駆化合物および使用方法
WO2005081752A2 (fr) 2004-02-09 2005-09-09 Amulet Pharmaceuticals, Inc. Polymeres liberant du monoxyde d'azote
US7569559B2 (en) * 2004-02-09 2009-08-04 Noxilizer, Inc. Nitric oxide-releasing molecules
EP1732577B1 (fr) * 2004-02-23 2013-04-10 Strategic Science & Technologies, LLC Administration topique de l-arginine, destinee a ameliorer l'aspect du corps et de la peau
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US20090105336A1 (en) * 2004-04-19 2009-04-23 Strategic Science & Technologies, Llc Beneficial Effects of Increasing Local Blood Flow
AU2005235308B2 (en) * 2004-04-19 2011-12-01 Strategic Science & Technologies, Llc Transdermal delivery of beneficial substances effected by a hostile biophysical environment
US20110028548A1 (en) * 2004-04-19 2011-02-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
JP2007534389A (ja) * 2004-04-29 2007-11-29 キューブ・メディカル・アクティーゼルスカブ 血管形成に用いるバルーン
US8518457B2 (en) * 2004-05-11 2013-08-27 Pulmonox Technologies Corporation Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant
EP1755715A4 (fr) 2004-05-11 2010-03-24 Sensormedics Corp Dosage intermittent d'oxyde nitrique gazeux
WO2006037105A2 (fr) 2004-09-27 2006-04-06 Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Polymeres diazeniumdiolates a base d'acrylonitrile liberant du monoxyde d'azote et compositions, dispositifs medicaux et utilisations correspondantes
US20070154570A1 (en) * 2004-09-29 2007-07-05 Miller Christopher C Use of nitric oxide in the treatment and disinfection of biofilms
US8067464B2 (en) 2004-10-04 2011-11-29 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
US20080300292A1 (en) * 2004-11-08 2008-12-04 Nitromed, Inc Nitrosated and Nitrosylated Compounds, Compositions and Methods for the Treatment of Ophthalmic Disorders
AU2006336387A1 (en) * 2005-02-16 2007-08-02 Nicox S.A. Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use
JP2008531697A (ja) * 2005-02-28 2008-08-14 ニトロメッド インコーポレーティッド 酸化窒素増強基を含む心血管化合物、組成物および使用法
CA2597444A1 (fr) * 2005-03-09 2006-09-21 Nitromed, Inc. Sels organiques d'antagonistes de l'angiotensine ii augmentant le taux de monoxyde d'azote endogene, compositions et procedes d'utilisation correspondants
JP2008535858A (ja) * 2005-04-07 2008-09-04 ニトロメッド インコーポレーティッド 心不全における遺伝リスク、すなわちｎｏｓ３の遺伝子変異の影響の評価方法
US20090048219A1 (en) * 2005-05-23 2009-02-19 Nitromed Inc. Organic nitric oxide donor salts of nonsteroidal antiinflammatory compounds, compositions and methods of use
JP5274248B2 (ja) 2005-05-27 2013-08-28 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 酸化窒素治療及び医生物的応用のための酸化窒素放出粒子
US20090018091A1 (en) * 2005-08-02 2009-01-15 Nitromed, Inc. Nitric Oxide Enhancing Antimicrobial Compounds, Compositions and Methods of Use
US8021679B2 (en) 2005-08-25 2011-09-20 Medtronic Vascular, Inc Nitric oxide-releasing biodegradable polymers useful as medical devices and coatings therefore
US20090192128A1 (en) * 2005-10-04 2009-07-30 Nitromed Inc. Genetic risk assessment in heart failure: impact of genetic variation of beta 1 adrenergic receptor gly389arg polymorphism
US7928079B2 (en) * 2005-10-31 2011-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Polysaccharide-derived nitric oxide-releasing carbon-bound diazeniumdiolates
WO2007059311A2 (fr) * 2005-11-16 2007-05-24 Nitromed, Inc. Composes furoxane, compositions et procedes d’utilisation
US20070116785A1 (en) * 2005-11-18 2007-05-24 Miller Christopher C Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant
US20070196327A1 (en) * 2005-12-06 2007-08-23 Amulet Pharmaceuticals, Inc. Nitric oxide releasing polymers
WO2007075541A2 (fr) * 2005-12-20 2007-07-05 Nitromed, Inc. Composes a l'acide glutamique activateurs d'oxyde nitrique, compositions et procedes d'utilisation
CA2647859C (fr) 2006-03-29 2016-01-05 Nitromed, Inc. Prostaglandines amplificatrices d'oxyde nitrique, compositions et methodes d'utilisation
US8241619B2 (en) 2006-05-15 2012-08-14 Medtronic Vascular, Inc. Hindered amine nitric oxide donating polymers for coating medical devices
US8079998B2 (en) * 2006-10-20 2011-12-20 Pulmonox Technologies Corporation Methods and devices for the delivery of therapeutic gases including nitric oxide
US20080193566A1 (en) * 2007-02-09 2008-08-14 Miller Christopher C Use of high dose concentrations of gaseous nitric oxide
US7811600B2 (en) 2007-03-08 2010-10-12 Medtronic Vascular, Inc. Nitric oxide donating medical devices and methods of making same
US8273828B2 (en) 2007-07-24 2012-09-25 Medtronic Vascular, Inc. Methods for introducing reactive secondary amines pendant to polymers backbones that are useful for diazeniumdiolation
US20090222088A1 (en) * 2008-02-29 2009-09-03 Medtronic Vascular, Inc. Secondary Amine Containing Nitric Oxide Releasing Polymer Composition
JP5529762B2 (ja) * 2008-03-07 2014-06-25 ユニバーシティー オブ ユタ リサーチ ファンデーション 活性化一酸化窒素ドナーならびにその作製および使用方法
US20090232863A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Biodegradable Carbon Diazeniumdiolate Based Nitric Oxide Donating Polymers
US20090232868A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Nitric Oxide Releasing Polymer Composition
US20100098733A1 (en) * 2008-10-16 2010-04-22 Novan, Inc. Nitric oxide releasing particles for oral care applications
US8158187B2 (en) 2008-12-19 2012-04-17 Medtronic Vascular, Inc. Dry diazeniumdiolation methods for producing nitric oxide releasing medical devices
EP2517736B1 (fr) 2009-02-23 2014-03-26 Noxilizer, Inc. Dispositif de stérilisation par gaz
US8709465B2 (en) 2009-04-13 2014-04-29 Medtronic Vascular, Inc. Diazeniumdiolated phosphorylcholine polymers for nitric oxide release
HUE037163T2 (hu) 2009-06-09 2018-08-28 Prolong Pharmaceuticals Llc Hemoglobin készítmények
US12138268B2 (en) 2009-06-24 2024-11-12 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
CN102481275B (zh) 2009-06-24 2014-07-23 战略科学技术有限公司 含有布洛芬的表面组合物
EP2445493A1 (fr) 2009-06-24 2012-05-02 Strategic Science & Technologies, LLC Composition topique contenant du naproxène
US9919072B2 (en) 2009-08-21 2018-03-20 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
ES2958410T3 (es) 2009-08-21 2024-02-08 Novan Inc Geles tópicos
WO2011047013A1 (fr) * 2009-10-13 2011-04-21 Novan, Inc. Revêtements libérant de l'oxyde nitrique
WO2011060215A1 (fr) 2009-11-13 2011-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Composés diazéniumdiolatés, compositions pharmaceutiques et procédé de traitement du cancer
US8633177B2 (en) 2010-03-19 2014-01-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitroxyl (HNO) releasing compounds and uses thereof in treating diseases
WO2011146371A1 (fr) * 2010-05-21 2011-11-24 Merck Sharp & Dohme Corp. Dérivés cyclohexyliques de diolate de diazénium
RU2013124814A (ru) 2010-10-29 2014-12-10 Мерк Шарп Энд Домэ Корп. Гетероциклические производные диазенийдиолата
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
CN105920603B (zh) 2010-12-29 2022-02-11 战略科学与技术有限责任公司 勃起功能障碍和其它适应症的治疗
WO2012092523A1 (fr) 2010-12-29 2012-07-05 Strategic Science & Technologies, Llc Systèmes et procédés de traitement d'allergies et autres indications
EP2681286B1 (fr) 2011-02-28 2018-08-15 Novan, Inc. Particules de silice modifiées par des groupements s-nitrosothiols libérant de l'oxyde nitrique et procédés de fabrication associés
JO3350B1 (ar) * 2011-03-07 2019-03-13 Merck Sharp & Dohme مشتقات حلقية غير متجانسة محتوية على مجموعات أمينو أولية ومركبات داي أزينيومديولات
WO2013059433A2 (fr) * 2011-10-21 2013-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Composés diazéniumdiolatés hybrides, compositions pharmaceutiques et procédé de traitement du cancer
EP2875056B1 (fr) 2012-07-17 2020-05-13 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Polymères à base de polyvinylpyrrolidone diazéniumdiolés et libérant de l'oxyde nitrique, compositions, dispositifs médicaux et applications associées
WO2014163093A1 (fr) * 2013-04-01 2014-10-09 テルモ株式会社 Composition d'enrobage et dispositif médical
CA2997896A1 (fr) 2015-09-09 2017-03-16 Advanced Inhalation Therapies (Ait) Ltd. Traitement par inhalation d'oxyde nitrique pour nourrissons atteints de bronchiolite
AU2018247167B2 (en) * 2017-03-28 2024-05-16 The University Of North Carolina At Chapel Hill Nitric oxide-releasing polyaminoglycosides as biodegradable antibacterial scaffolds and methods pertaining thereto

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122080C (fr) *
DD122080A1 (fr) 1975-05-28 1976-09-12
JPS606651A (ja) * 1983-06-27 1985-01-14 Oji Koonsutaac Kk １−ヒドロキシ−２−ヒドロキシジアゼニウムオキシジルプロパン及びその塩
US4954526A (en) * 1989-02-28 1990-09-04 The United States Of America As Represented By The Department Of Health And Human Services Stabilized nitric oxide - primary amine complexes useful as cardiovascular agents
US5721365A (en) 1989-09-15 1998-02-24 Us Health N-substituted piperazine NONOates
US5212204A (en) * 1989-10-18 1993-05-18 The United States Of America As Represented By The Department Of Health And Human Services Antihypertensive compositions and use thereof
US5155137A (en) 1990-09-20 1992-10-13 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Complexes of nitric oxide with polyamines
ES2112332T3 (es) * 1991-09-24 1998-04-01 Us Health Derivados de substitucion de oxigeno de productos de adicion de nucleofilo-oxido nitrico utilizados como promedicamentos donadores de oxido nitrico.
GB9127376D0 (en) 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
US5374710A (en) 1993-05-26 1994-12-20 Regents Of The University Of California Compounds which release nitric oxide upon illumination
JPH09501918A (ja) 1993-08-12 1997-02-25 アストラ・アクチエボラーグ 酸化窒素合成酵素活性を有するアミジン誘導体
US5674894A (en) 1995-05-15 1997-10-07 G.D. Searle & Co. Amidine derivatives useful as platelet aggregation inhibitors and vasodilators
US5770645A (en) * 1996-08-02 1998-06-23 Duke University Medical Center Polymers for delivering nitric oxide in vivo
EP1000023B1 (fr) * 1997-07-03 2011-02-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES Nouveaux diazeniumdiolates derives d'amidine et d'enamine liberant du monoxyde d'azote, compositions les contenant, leurs utilisations et leurs procedes de fabrication

Also Published As

Publication number Publication date
JP2002510320A (ja) 2002-04-02
AU8281598A (en) 1999-01-25
WO1999001427A2 (fr) 1999-01-14
EP1000023A2 (fr) 2000-05-17
AU726861B2 (en) 2000-11-23
WO1999001427A3 (fr) 1999-03-25
US6911478B2 (en) 2005-06-28
US20010025052A1 (en) 2001-09-27
US6511991B2 (en) 2003-01-28
US20040180863A1 (en) 2004-09-16
US20030166619A1 (en) 2003-09-04
CA2293501A1 (fr) 1999-01-14
JP4856295B2 (ja) 2012-01-18
DE69842142D1 (de) 2011-04-07
US6232336B1 (en) 2001-05-15
JP2010168390A (ja) 2010-08-05
ATE499343T1 (de) 2011-03-15
US6750254B2 (en) 2004-06-15

Similar Documents

Publication Publication Date Title
EP1000023B1 (fr) Nouveaux diazeniumdiolates derives d'amidine et d'enamine liberant du monoxyde d'azote, compositions les contenant, leurs utilisations et leurs procedes de fabrication
AU2003261174B2 (en) Novel nitric oxide-releasing amidine diazeniumdiolates, compositions and uses thereof and method of making same
US6673338B1 (en) Nitric oxide-releasing imidate and thioimidate diazeniumdiolates, compositions, uses thereof and method of making same
SU784783A3 (ru) Способ получени производных лейрозидина или их солей
US3972932A (en) Novel 2,6-disubstituted phenyl-aminoguanidine compounds
JPS61227529A (ja) アクタガルジンの塩基性モノアミド誘導体及びその付加塩
JPS5911578B2 (ja) ビス−カルバミルグアニジノアザアルカン抗菌性化合物及びその製造方法
US4515954A (en) Metal chelates of anthracene-9,10-bis-carbonylhydrazones
US2516108A (en) Abaleoxyalkylemibazoiilnes
US3901944A (en) 1,3-bis(substituted benzylideneamino)guanidines
GB2050364A (en) Bis (4-demethoxydaunorubicin) dihydrazone derivatives and pharmacologically acceptable salts thereof
KR100630291B1 (ko) ((아미노이미노메틸)아미노)알칸카르복스아미드 및 이의치료법에서의 용도
GB2068963A (en) Basic ethers of 4-hydroxy-benzophenones acting as beta-blocking agents and relevant preparation processes
GB1380145A (en) Acetamidine derivatives process for preparing the same and pharma ceutical uses thereof
FI80440B (fi) Analogifoerfarande foer framstaellning av terapeutiskt anvaendbara afidkolanderivat.
US3712921A (en) Alpha,alpha,alpha,alpha',alpha',alpha'-hexafluorodi-m-tolylamine derivatives
US3903081A (en) 1,4-Bis-(5{40 -nitroimidazolyl-2{40 -methylene-imino)-piperazines
US3164585A (en) Hydrazones of cyclichalovinylaldehydes
JPH05262760A (ja) チオキサンテノン類およびその抗腫瘍剤
RU2030402C1 (ru) S-(2-пиридинийэтил)-n-метилтиурония дийодид, проявляющий радиозащитную активность
US3862936A (en) Mannich derivatives of 4,4{40 -dihydroxy-3,3{40 dinitrobenzophenone
US3398144A (en) Substituted 3-amino-2'-hydroxyacrylophenones
CA2431181A1 (fr) Nootropes
GB1244026A (en) Antibacterial agents and process for their preparation
GB983118A (en) Improvements in and relating to substituted pteridine compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000202

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20060904

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69842142

Country of ref document: DE

Date of ref document: 20110407

Kind code of ref document: P

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 69842142

Country of ref document: DE

Effective date: 20110407

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20110223

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110623

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110223

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110603

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110524

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110223

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110223

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110223

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110223

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110223

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110223

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20110805

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20110725

Year of fee payment: 14

Ref country code: DE

Payment date: 20110727

Year of fee payment: 14

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20111124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110731

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 69842142

Country of ref document: DE

Effective date: 20111124

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110731

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110223

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110701

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20120701

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20130329

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120701

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130201

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110701

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 69842142

Country of ref document: DE

Effective date: 20130201